Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Key clinical point: Upfront PD-L1 inhibition added to chemotherapy may improve outcomes in triple-negative breast cancers.
Major finding: In patients with PD-L1 combined positive score greater than 10, the HR for progression with pembrolizumab/chemotherapy was 0.65 (P = .0012).
Study details: Randomized, controlled trial in 843 patients with triple-negative breast cancer.
Disclosures: The study was funded by Merck. Dr. Cortes disclosed honoraria from, a consulting/advisory role for, and institutional research funding from Merck and others.
Citation:
Cortes J et al. ASCO 2020, Abstract 1000.